License and Collaboration Agreement with ImmuneOnco (Details) - USD ($) $ in Millions |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Apr. 30, 2025 |
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2024 |
Jan. 05, 2026 |
Aug. 31, 2025 |
Jul. 31, 2025 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
| Development cost | $ 5.0 | ||||||
| Additional accrual for prepayment of development costs | $ 5.0 | ||||||
| Axion | |||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
| Upfront payment | $ 10.0 | ||||||
| Development cost | $ 5.0 | ||||||
| Collaboration agreement costs incurred | 0.3 | $ 4.3 | |||||
| Axion | Commercial, development and regulatory milestones | |||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||||
| Development payment | 0.2 | $ 1.8 | $ 10.0 | ||||
| Reduction of research and development expense | $ 1.6 | ||||||